What the changes say
- FDA oversight risks deepen, including field-action reporting, follow-up failures, possible warning letters, and consent decree discussions.
- Billing and collections are newly emphasized, including payor rates, Medicare and Medicaid rules, patient cost-sharing, and write-offs.
- Tariffs, FDA workforce reductions, trade tensions, and executive orders add uncertainty to regulation, approvals, supply chains, and costs.
- The company continues to depend overwhelmingly on reimbursement and market acceptance of its iRhythm Services.
What changed since the prior 10-K
New
- NewRisks Related to Our Industry, Business and Operations
requirements, coverage criteria, procedures, or expectations. We also bill insured patients for co-payments, co-insurance, and deductible amounts, as well as bill self-pay patients directly
Billing and collecting from payors and patients may be delayed or reduced by differing rates, coverage rules, cost-sharing, errors, write-offs, and long collection cycles.
- NewRisks Related to Our Industry, Business and Operations
the filing of reports may increase regulator and public scrutiny, especially given that these reports are typically publicly available information in most jurisdictions, including the United States, which could harm our business
FDA and other regulators may require public reporting and communications for iRhythm ACM System corrections, removals, recalls, or field advisories, increasing scrutiny.
- NewRisks Related to Our Industry, Business and Operations
publicly available on FDA’s website and have been the subject of a high degree of media and industry attention, which subjects us to additional scrutiny
Failure to complete FDA follow-up commitments could escalate to additional warning letters or consent decree discussions, increasing costs, management distraction, and reputational harm.
- NewRisks Related to Healthcare Regulatory Matters
expansion), and rolling back regulatory initiatives adopted under the previous administration. We cannot predict whether industry initiatives to seek tariff carve-outs for devices or other life sciences goods and products will be successful
Tariffs, FDA workforce reductions, trade tensions, and executive orders could raise costs, delay FDA guidance and reviews, and restrict access to regulatory approvals.
- NewRisks Related to Intellectual Property
outcome of such litigation. In the event of an adverse judgment, a court could hold that some or all of our asserted intellectual property rights are not infringed, or are invalid or unenforceable, and could award attorneys’ fees
Unregistered intellectual property and proprietary technology may be copied, misappropriated, designed around, or receive weaker protection under foreign laws.
Reworded
- 94% rewrittenRisks Related to Healthcare Regulatory Matters
Our business could be negatively impacted by changes in the United States political environment
The political-risk discussion now adds post-inauguration proposals, potential device tariffs, FDA workforce reductions, trade restrictions, and possible approval or guidance delays.
- 83% rewrittenRisks Related to Healthcare Regulatory Matters
Changes in applicable laws or regulations or the interpretation or enforcement policies of regulators governing our medical devices, IDTFs and iRhythm Services may constrain or require us to restructure our operations or adapt certain business strategies, which may harm our revenue and operating results
The risk now specifically identifies FDA’s Product Code QYX and its regulation of MCT devices, including Zio AT and new 510(k) applicants.
Was: Changes in applicable laws or regulations or the interpretation or enforcement policies of regulators governing our IDTFs and Zio Services may constrain or require us to restructure our operations or adapt certain business strategies which may harm our revenue and operating results
- 79% rewrittenRisks Related to Our Industry, Business and Operations
We may not be able to obtain additional marketing authorizations in a timely fashion, or at all, which could harm our ability to introduce new or enhanced products in a timely manner and to meet market expectations for the provision of the services, which in turn could harm our future growth
The body mainly updates the service name from Zio Services to iRhythm Services while retaining the existing quality, recall, enforcement, and DOJ risks.
- 63% rewrittenRisks Related to Financial and Accounting Matters
Our failure to maintain an effective system of internal controls, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations
The prior reference to identified material weaknesses is replaced with ongoing costs and management oversight to maintain and improve financial reporting controls.
Was: In the future we may identify additional material weaknesses or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations
- 45% rewrittenRisks Related to Our Industry, Business and Operations
Our revenue relies on our iRhythm Services, which are currently our only offerings. If our iRhythm Services or future service offerings fail to gain, or lose, market acceptance, our business will suffer
The discussion updates Zio Services to iRhythm Services while retaining the risk that new offerings may fail to gain acceptance or add revenue.
Was: Our revenue relies on our Zio Services, which are currently our only offerings. If our Zio Services or future service offerings fail to gain, or lose, market acceptance, our business will suffer
- 44% rewrittenRisks Related to Our Industry, Business and Operations
If reimbursement or other payment for our iRhythm Services is reduced or modified in the United States or in our international markets, including through cost containment measures or changes to policies with respect to coding, coverage, and pricing, our business could suffer
The discussion updates Zio Services to iRhythm Services; the dependence on Medicare and commercial payors and CMS rate reductions remains unchanged.
Was: If reimbursement or other payment for our Zio Services is reduced or modified in the United States or in our international markets, including through cost containment measures or changes to policies with respect to coding, coverage, and pricing, our business could suffer
- 44% rewrittenRisks Related to Our Industry, Business and Operations
If we are unable to expand the number of third-party commercial payors with which we contract or expand coverage for existing third-party commercial payors, our commercial success could be impacted
No substantive risk change is apparent; the discussion continues to cover uncertainty and cost of securing commercial-payor contracts and coverage.
- 42% rewrittenRisks Related to Our Debt
We may be impacted by domestic and global economic and political conditions, as well as natural disasters, severe weather, pandemics, and other catastrophic events, which could adversely affect our business, financial condition, or results of operations
The geopolitical examples now also include Venezuela and refer to conflicts in the Middle East, with the broader economic and operational risks otherwise retained.
Was: We may be impacted by domestic and global economic and political conditions, as well as natural disasters, pandemics, and other catastrophic events, which could adversely affect our business, financial condition, or results of operations
- 41% rewrittenRisks Related to Our Industry, Business and Operations
We have incorporated and continue to work to further incorporate AI into our products, services, and internal operations. Implementation of AI and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business
Was: We have incorporated and continue to work to further incorporate AI into our products, services, and internal operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business
- 41% rewrittenRisks Related to Financial and Accounting Matters
We have a history of operating losses and may not achieve or sustain profitability in the future
- 40% rewrittenRisks Related to Privacy and Security
Cyber-attacks aimed at accessing our devices and services, or related devices and services, and modifying or using them in a way inconsistent with our FDA marketing authorizations and regulatory certifications or approvals in the EU, Switzerland, Japan and the UK, could create risks to patients
Was: Cyber-attacks aimed at accessing our devices and services, or related devices and services, and modifying or using them in a way inconsistent with our FDA marketing authorizations and regulatory certifications in the EU and the UK, could create risks to patients
- 34% rewrittenRisks Related to Other Legal and Regulatory Matters
We are subject to legal proceedings and government investigations that could adversely affect our business, financial condition, and results of operations
- 31% rewrittenRisks Related to Other Legal and Regulatory Matters
We could be subject to changes in our tax rates, new U.S. or international tax legislation, or additional tax liabilities
- 30% rewrittenRisks Related to Our Industry, Business and Operations
Audits or denials of our claims by government agencies or payors could expose us to recoupment, regulatory scrutiny, and penalties
- 28% rewrittenRisks Related to Our Debt
Our indebtedness could adversely affect our financial health and our ability to respond to changes in our business
- 26% rewrittenRisks Related to Our Industry, Business and Operations
We may face risks associated with acquisitions of companies, products, and technologies and our business could be harmed if we are unable to address these risks
- 23% rewrittenRisks Related to Our Industry, Business and Operations
International expansion of our business exposes us to market, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States
- 22% rewrittenRisks Related to Healthcare Regulatory Matters
As a Medicare-enrolled IDTF, we are prohibited from directly soliciting patients for diagnostic medical procedures. While we can engage in general marketing initiatives, consistent with applicable law, we cannot make telephone, computer, and in-person contacts for the purpose of soliciting business for our IDTF
- 22% rewrittenRisks Related to Our Industry, Business and Operations
If we are unable to keep up with demand for our iRhythm Services, our revenue could be impaired, market acceptance for our iRhythm Services could be harmed, and physicians may instead order our competitors’ services
Was: If we are unable to keep up with demand for our Zio Services, our revenue could be impaired, market acceptance for our Zio Services could be harmed, and physicians may instead order our competitors’ services
- 21% rewrittenRisks Related to Intellectual Property
Our inability to adequately protect our intellectual property could allow our competitors and others to produce devices and offer services based on our technology, which could substantially impair our ability to compete
All 49 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Industry, Business and Operations
- 01If reimbursement or other payment for our iRhythm Services is reduced or modified in the United States or in our international markets, including through cost containment measures or changes to policies with respect to coding, coverage, and pricing, our business could suffer44% rewritten
- 02If we are unable to expand the number of third-party commercial payors with which we contract or expand coverage for existing third-party commercial payors, our commercial success could be impacted44% rewritten
- 03Our revenue relies on our iRhythm Services, which are currently our only offerings. If our iRhythm Services or future service offerings fail to gain, or lose, market acceptance, our business will suffer45% rewritten
- 04requirements, coverage criteria, procedures, or expectations. We also bill insured patients for co-payments, co-insurance, and deductible amounts, as well as bill self-pay patients directlyNew
- 05Audits or denials of our claims by government agencies or payors could expose us to recoupment, regulatory scrutiny, and penalties30% rewritten
- 06We may not be able to obtain additional marketing authorizations in a timely fashion, or at all, which could harm our ability to introduce new or enhanced products in a timely manner and to meet market expectations for the provision of the services, which in turn could harm our future growth79% rewritten
- 07the filing of reports may increase regulator and public scrutiny, especially given that these reports are typically publicly available information in most jurisdictions, including the United States, which could harm our businessNew
- 08publicly available on FDA’s website and have been the subject of a high degree of media and industry attention, which subjects us to additional scrutinyNew
- 09If we are unable to keep up with demand for our iRhythm Services, our revenue could be impaired, market acceptance for our iRhythm Services could be harmed, and physicians may instead order our competitors’ services22% rewritten
- 10We depend on third-party vendors for the supply and manufacture of certain components of our iRhythm ACM Systems, as well as for other aspects of our operations
- 11We have incorporated and continue to work to further incorporate AI into our products, services, and internal operations. Implementation of AI and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business41% rewritten
- 12Our ability to compete depends on our ability to innovate successfully
- 13We have entered into in the past, and may explore or enter into in the future, development or collaboration agreements with third parties. These development and collaboration agreements may not result in the development of commercially viable devices or the generation of significant future revenues
- 14International expansion of our business exposes us to market, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States23% rewritten
- 15Our success depends on our ability to attract and retain senior management and key personnel
- 16Our continued rapid growth could strain our personnel resources and infrastructure, and if we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed
- 17Failure to receive the iRhythm ACM System patches used for the provision of the iRhythm Services we provide may result in a loss of capital as well as revenue where the receipt of returned devices and processing of data retrieved from returned devices is required to provide our iRhythm Services
- 18We may face risks associated with acquisitions of companies, products, and technologies and our business could be harmed if we are unable to address these risks26% rewritten
Risks Related to Healthcare Regulatory Matters
- 19If we fail to comply with medical device, healthcare, and other governmental regulations, we could face substantial penalties and our business, results of operations, and financial condition could be adversely affected
- 20Changes in applicable laws or regulations or the interpretation or enforcement policies of regulators governing our medical devices, IDTFs and iRhythm Services may constrain or require us to restructure our operations or adapt certain business strategies, which may harm our revenue and operating results83% rewritten
- 21Our business could be negatively impacted by changes in the United States political environment94% rewritten
- 22expansion), and rolling back regulatory initiatives adopted under the previous administration. We cannot predict whether industry initiatives to seek tariff carve-outs for devices or other life sciences goods and products will be successfulNew
- 23As a Medicare-enrolled IDTF, we are prohibited from directly soliciting patients for diagnostic medical procedures. While we can engage in general marketing initiatives, consistent with applicable law, we cannot make telephone, computer, and in-person contacts for the purpose of soliciting business for our IDTF22% rewritten
Risks Related to Financial and Accounting Matters
- 24Our failure to maintain an effective system of internal controls, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations63% rewritten
- 25Our financial results may fluctuate significantly from quarter-to-quarter and may not fully reflect the underlying performance of our business
- 26We have a history of operating losses and may not achieve or sustain profitability in the future41% rewritten
- 27We may require additional capital to support the growth of our business, and this capital might not be available on acceptable terms, if at all
- 28Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability
Risks Related to Other Legal and Regulatory Matters
- 29We are subject to legal proceedings and government investigations that could adversely affect our business, financial condition, and results of operations34% rewritten
- 30Compliance with requirements of being a public company may strain our resources and divert management’s attention
- 31We could be subject to changes in our tax rates, new U.S. or international tax legislation, or additional tax liabilities31% rewritten
- 32We may be liable for contamination or other harm caused by materials that we handle, and changes in environmental regulations could cause us to incur additional expense
Risks Related to Intellectual Property
- 33Our inability to adequately protect our intellectual property could allow our competitors and others to produce devices and offer services based on our technology, which could substantially impair our ability to compete21% rewritten
- 34outcome of such litigation. In the event of an adverse judgment, a court could hold that some or all of our asserted intellectual property rights are not infringed, or are invalid or unenforceable, and could award attorneys’ feesNew
Risks Related to Privacy and Security
- 35Cyber-attacks aimed at accessing our devices and services, or related devices and services, and modifying or using them in a way inconsistent with our FDA marketing authorizations and regulatory certifications or approvals in the EU, Switzerland, Japan and the UK, could create risks to patients40% rewritten
Risks Related to Our Common Stock
- 36If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
- 37Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors
- 38Anti-takeover effects of our charter documents and Delaware law could make a merger, tender offer, or proxy contest difficult, thereby depressing the trading price of our common stock
- 39Moreover, Section 203 of the DGCL may discourage, delay, or prevent a change of control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock
- 40We do not intend to pay dividends for the foreseeable future
Risks Related to Our Debt
- 41Our indebtedness could adversely affect our financial health and our ability to respond to changes in our business28% rewritten
- 42Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our indebtedness
- 43The capped call transactions may affect the value of our common stock
- 44We are subject to counterparty risk with respect to the capped call transactions
- 45Conversion of the 2029 Notes will, to the extent we deliver shares upon conversion of such 2029 Notes, dilute the ownership interest of existing stockholders, including holders who had previously converted their 2029 Notes, or may otherwise depress our stock price
- 46The conditional conversion feature of the 2029 Notes, if triggered, may adversely affect our financial condition and operating results
- 47The accounting method for convertible debt securities that may be settled in cash, such as the 2029 Notes, could have a material effect on our reported financial results
- 48We may be impacted by domestic and global economic and political conditions, as well as natural disasters, severe weather, pandemics, and other catastrophic events, which could adversely affect our business, financial condition, or results of operations42% rewritten
- 49Environmental, social, and corporate governance (“ESG”) regulations, policies, and provisions may make our supply chain more complex and may adversely affect our relationships with customers
Other iRhythm Holdings 10-Ks
- FY2024 10-K risk factors44 risks
This is an initial filing with no prior year risk comparison. The company relies almost entirely on its Zio services and is heavily exposed to Medicare and commercial reimbursement rates, FDA regulations, and intellectual property protection.
Filed Feb 20, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.